TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00273624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04063540
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by Amiloride vs placebo in crossover
Study: NCT00016341
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02393612
Drug: Anplag tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anplag tab 100mg is administrated to patients with PAD for 12 weeks
Study: NCT00941707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
Study: NCT04145193
Drug: Standard of Care - mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
Study: NCT02121002
Drug: Voltaren Topical Gel, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opaque, white gel
Study: NCT02121002
Drug: Vehicle Diclofenac Sodium Topical Gel
Normalized name: diclofenac sodium Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opaque, white gel
Study: NCT01891084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
Study: NCT01891084
Drug: Backup NSAID ibuprofen
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
Study: NCT00811395
Drug: Interferon-β [IFN-β]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study: NCT00052585
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00052585
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02728180
Drug: Xingnaojing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
Study: NCT04572724
Drug: RAS Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
Study: NCT01985334
Drug: ICS
Normalized name: ICSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT00914589
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Study: NCT01290341
Drug: NAFT-600 (naftin 2 % gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical; applied once daily for two weeks
Study: NCT01290341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical; applied once daily for two weeks.
Study: NCT02422706
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KLacid twice daily
Study: NCT02422706
Drug: Doxicycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vibramycin 100 mg twice daily
Study: NCT00960141
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, taken orally once daily at bed time for 2 weeks
Study: NCT00182975
Drug: DHEA replacement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04291092
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy for brain metastasis
Study: NCT04291092
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for brain metastasis
Study: NCT01095796
Drug: Atripla Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Atripla tablet administered orally once daily prior to bedtime
Study: NCT03082690
Drug: DuoGel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% IQP-0528 in gel formulation
Study: NCT03349723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single rising dose groups
Study: NCT00779116
Drug: Zyrtec® (cetirizine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
Study: NCT03818893
Drug: Combination of GEN0101 and Pembrolizmub
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Combination immunotherapy GEN0101 and Pembrolizmub
Study: NCT04192916
Drug: DOACs
Normalized name: Doans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants
Study: NCT04050540
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
Study: NCT01128855
Drug: 3 mg/kg GSK2402968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injection
Study: NCT01128855
Drug: 6 mg/kg GSK2402968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injection
Study: NCT01128855
Drug: 12 mg/kg GSK2402968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous injection
Study: NCT01602224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01989455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: normal saline solution.
Study: NCT03966898
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT00263094
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00999167
Drug: HPN-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: 6 mL BID for 16 weeks.
Study: NCT00999167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: same as experimental arm
Study: NCT01428479
Drug: GR121167 Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
Study: NCT01428479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered intravenously.
Study: NCT02516306
Drug: EV06 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01417546
Drug: NHS-IL-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
Study: NCT02217839
Drug: DG3173
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217839
Drug: DG3173 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04452318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC or IM injections
Study: NCT01196091
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
Study: NCT03928522
Drug: hand mixed tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: hand mixed tobramycin into cement
Study: NCT01196091
Drug: Placebo every 2 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
Study: NCT01196091
Drug: Placebo every 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection for 52 weeks.
Study: NCT01196091
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01649895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills as adjunct to internet-based cognitive-behaviour therapy
Study: NCT04214106
Drug: intravenous Thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients who received Thiamine,100-500 mg/day for at least one day
Study: NCT02620501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% Normal Saline
Study: NCT02918617
Drug: Control toothpaste containing Novamin® technology
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Control toothpaste containing 1500 ppm fluoride as MFP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Test toothpaste with nano-HAP (high concentration)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Test toothpaste with nano-HAP (low concentration)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Control toothpaste without nano-HAP
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02918617
Drug: Test toothpaste with nano-HAP (medium concentration)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Test cream with nano-HAP (higher concentration)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918617
Drug: Control cream without nano-HAP
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03577275
Drug: NST-4016 600mg
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Likely maximum therapeutic dose of NST-4016
Study: NCT03577275
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for comparison with moxifloxacin and potential NST-4016 effects
Study: NCT03577275
Drug: NST-4016 2000mg
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic dose of NST-4016
Study: NCT00002682
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002682
Drug: Tetracycline Hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00259545
Drug: Retarded Release Phosphatidylcholine (rPC)
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03346434
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, subcutaneous (SC)
Study: NCT04075955
Drug: Zyprexa® (OLANZapine 5MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)
Study: NCT04075955
Drug: Emend® (Aprepitant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)
Study: NCT01714336
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
Study: NCT02202161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
Study: NCT02828618
Drug: 3 cycles of standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 more cycles (for a total of 6) of standard chemotherapy after IDS
Study: NCT01830829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00474136
Drug: Intravenous diclofenac sodium (DIC075V) 18.75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIC075V 18.75 mg
Study: NCT00474136
Drug: Intravenous diclofenac sodium (DIC075V) 37.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIC075V 37.5 mg
Study: NCT00474136
Drug: Oral diclofenac potassium 50 mg
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac potassium 50 mg
Study: NCT00665340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00383552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo metered dose inhaler twice a day for 26 weeks
Study: NCT02172872
Drug: standard combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days
Study: NCT00191438
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01688479
Drug: Essex® cream (Schering-Plough), aqueous cream without parabens
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00280917
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02169466
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC, Opicapone
Study: NCT02169466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC, Placebo
Study: NCT02169466
Drug: Madopar® HBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: controlled-release levodopa 100 mg/benserazide 25 mg
Study: NCT00171327
Drug: valsartan, fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03323385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily
Study: NCT03831607
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Study: NCT00033293
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02490904
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
Study: NCT02490904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blinded Placebo administered for 4 days at 25mg every 12 hours
Study: NCT01339676
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically appearing once weekly peroral placebo capsules
Study: NCT02802735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT00854568
Drug: CEOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Study: NCT00854568
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Study: NCT00957034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch
Study: NCT00957034
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 or 450 micrograms/day transdermal testosterone patch
Study: NCT00533910
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as the experimental arm
Study: NCT01086813
Drug: AZD3043
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose/IV, bolus over 60secs - infusion over 30 mins
Study: NCT02818335
Drug: LY3023414 Test Fasted
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT00021281
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00021281
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00021281
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02324413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00529113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules x 28 days
Study: NCT02675946
Drug: CGX1321
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00609336
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00631969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Study: NCT04017221
Drug: Other treatment combinations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
Study: NCT00675181
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg per os
Study: NCT00675181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os
Study: NCT03166228
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline as distension medium as long as diathermy is not in use
Study: NCT01137708
Drug: ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
Study: NCT01137708
Drug: CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
Study: NCT03166228
Drug: 1.5% Glycine only
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% Glycine alone during hysteroscopy as long as diathermy is in use
Study: NCT03838666
Drug: Suspension of human autologous MSC 3P
Normalized name: microspheres of human albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
Study: NCT01205646
Drug: zoledronate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
Study: NCT00823472
Drug: Mild stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
Study: NCT02534376
Drug: ezetimibe 10mg-simvastatin 40mg
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
Study: NCT02515305
Drug: Placebo gel (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00997490
Drug: Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 tablets/day over 6 weeks
Study: NCT02099240
Drug: oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
Study: NCT01646736
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 1.0 intravenous every month.
Study: NCT04233801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00495885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, one tablet taken around bedtime
Study: NCT01996605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered spinally